{"database":"BioModels","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Txt":["https://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000946?filename=curation_notes.txt"],"Owl":["https://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000946?filename=Evans2005-biopax3.owl","https://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000946?filename=Evans2005-biopax2.owl"],"Xml":["https://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000946?filename=manifest.xml","https://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000946?filename=Evans2005.xml"],"Other":["https://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000946?filename=metadata.rdf","https://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000946?filename=Evans2005.cps","https://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000946?filename=figure2_abc_pH7.png","https://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000946?filename=Evans2005-octave.m","https://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000946?filename=Evans2005-matlab.m","https://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000946?filename=curation_image.png","https://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000946?filename=Evans2005.sedml","https://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000946?filename=Evans2005.ode"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"submitter":["Matthew Roberts"],"curationStatus":["Manually curated"],"modellingApproach":["ordinary differential equation model"],"levelVersion":["L2V4"],"full_dataset_link":["https://www.ebi.ac.uk/biomodels/BIOMD0000000946"],"isPrivate":["false"],"repository":["BioModels"],"modelFormat":["SBML"],"omics_type":["Models"],"tokenised_name":["Evans2005   Compartmental model for antineoplastic drug topotecan in breast cancer cells"],"publication_year":["2005"],"submissionId":["MODEL1805210001"],"publication_authors":["Neil D. Evans, Rachel J. Errington, Michael J. Chapman, Paul J. Smith, Michael J. Chappell, Keith R. Godfrey"],"first_author":["Neil D. Evans"],"publication":["10.1002/acs.856,\n                            A compartmental model for the in vitro uptake kinetics of the anti-cancer agent topotecan is proposed. This model provides a description of the activity of the drug, and subsequent delivery of active form to the nuclear DNA target. The unknown model parameters are estimated from two-photon laser-scanning microscopy data, which provide concentrations of topotecan (active plus inactive forms) in the extracellular region containing live human breast tumour cells (MCF-7 cell line), the cytoplasm and the nucleus. This determines an output structure for which the model is uniquely identifiable, that is, the unknown parameters are uniquely determined from noise-free, continuous and perfect data. The\nmodel allows in silico predictions of the dose dependence of target binding. Copyright 2005 John Wiley & Sons, Ltd.. null, 19.\n                            School of Engineering, University of Warwick, Coventry CV4 7AL, U.K. Department of Medical Biochemistry, University of Wales College of Medicine, Cardiff CF14 4XN, U.K. School of MIS-Mathematics, Coventry University, Coventry CV1 5FB, U.K. Department of Pathology, University of Wales College of Medicine, Cardiff CF14 4XN, U.K"],"submitter_mail":["mroberts@ebi.ac.uk"],"publication_doi":["10.1002/acs.856"],"submitter_affiliation":["EMBL-EBI"],"publicationId":["BIOMD0000000946"],"pubmed_abstract":["In this paper a compartmental modelling approach is applied to provide a mathematical description of the activity of the anti-cancer agent topotecan, and delivery to its nuclear DNA target following administration. The activity of topotecan in defined buffers is first modelled using a linear two compartment model that then forms the basis of a cell based model for drug activity in live cell experiments. An identifiability analysis is performed before parameter estimation to ensure that the model output (i.e., continuous, perfect and noise-free data) uniquely determines the parameters. Parameter estimation is performed using experimental data which offers concentrations of active and inactive forms of topotecan from high performance liquid chromatography methods."],"pubmed_title":["A mathematical model for the in vitro kinetics of the anti-cancer agent topotecan."],"pubmed_authors":["Evans Neil D ND, Errington Rachel J RJ, Shelley Michael M, Feeney Graham P GP, Chapman Michael J MJ, Godfrey Keith R KR, Smith Paul J PJ, Chappell Michael J MJ"],"additional_accession":[]},"is_claimable":false,"name":"Evans2005 - Compartmental model for antineoplastic drug topotecan in breast cancer cells","description":"\n      \n     Compartment model for the antineoplastic drug topotecan. Modelling drug in its active lactone and inactive hydroxy acid forms in the medium, extracellular, cytoplasm and nucleus.\n  \n    ","dates":{"last_modification":"2024-08-22","publication":"2024-09-02","submission":"2018-05-21"},"accession":"BIOMD0000000946","cross_references":{"sbo":["SBO:0000587","SBO:0000338","SBO:0000189","SBO:0000468"],"pubmed":["15094319"],"chebi":["CHEBI:63632","CHEBI:70727","CHEBI:25000","CHEBI:35610","CHEBI:35868","CHEBI:16991"],"obi":["OBI:0001285"],"biomodels__db":["MODEL1805210001","BIOMD0000000946"],"pw":["PW:0002367"],"pato":["PATO:0002355"],"go":["GO:0005634","GO:0005576","GO:0005737","GO:0065004","GO:0015562","GO:0005488"],"kegg__compound":["C11158"],"taxonomy":["9606"],"bto":["BTO:0000093","BTO:0000316"],"efo":["EFO:0000428"],"doi":["10.1002/acs.856"]}}